Bifidobacterium breve
Bifidobacterium breve is a species commonly found in the human gut, particularly in breastfed infants, where it plays a role in fermenting complex carbohydrates including human milk oligosaccharides. Research across multiple B. breve strains has examined metabolism of prebiotic substrates, production of short-chain fatty acids, and immune modulation in animal models. A small early randomized trial examined this strain in the context of Campylobacter enteritis, and in vitro work has characterized metabolic and epithelial cell interactions. Because this index entry is at the species level rather than a specific strain, findings vary considerably across strains and should not be generalized without strain-specific data. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 1,482 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 466 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
+17 more symptoms
Strains of this species
10 strains of Bifidobacterium breve in the index, with 223 linked papers between them.
Bifidobacterium breve M-16V
Bifidobacterium breve M-16V is a well-studied strain with a particular focus on infant and neonatal applications.
Bifidobacterium breve B-3
Bifidobacterium breve B-3 has been studied primarily in the context of metabolic health, with research spanning animal models and several randomized controlled trials in humans examining body fat and related metabolic ou…
Bifidobacterium breve BR03
Bifidobacterium breve BR03 is a named probiotic strain studied in randomized controlled trials spanning multiple research contexts.
Bifidobacterium breve CECT7263
Bifidobacterium breve CECT7263 is a human milk-derived strain studied in the context of infant feeding and early-life gut health.
Bifidobacterium breve MCC1274
Bifidobacterium breve MCC1274 has an emerging body of research focused primarily on brain-gut interactions and cognitive health.
Bifidobacterium breve A1
Bifidobacterium breve A1 has been studied in the context of cognitive health, including randomized, double-blind, placebo-controlled trials in older adults with mild cognitive impairment examining memory-related outcomes.
Bifidobacterium breve YIT12272
Bifidobacterium breve YIT12272 is a Gram-positive, anaerobic bacterium belonging to the Bifidobacterium genus, known for its predominance in infant gut microbiota.
Bifidobacterium breve Bif-07
Bifidobacterium breve Bif-07 is a commercial strain within the well-characterized B.
Bifidobacterium breve B632
Bifidobacterium breve B632 has been studied primarily in pediatric populations, often in combination with the related strain BR03, across several randomized controlled trials.
Bifidobacterium breve CBT-BR3
Bifidobacterium breve CBT BR3 is a commercially developed probiotic strain that has been studied primarily in animal models.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
2624 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.
Citations
Selected papers that name this strain.
-
[1]
PMID 41879960 →The beneficial effect of Bifidobacterium breve Br03 and Bifidobacterium breve B632 mixture in acute infectious diarrhea in children· Probiotics and Antimicrobial Proteins · 2026
-
[2]
PMID 42234385 →Bifidobacterium breve PRL2020 mitigates antibiotic-induced gut symptoms and dysbiosis in children treated with amoxicillin or amoxicillin-clavulanate· International Microbiology · 2026
-
[3]
PMID 41648756 →Eight weeks of treatment with probiotic Bifidobacterium breve, Bif195 lowers fatigue scores in patients with diarrhoea-predominant irritable bowel syndrome: results from a randomised, clinical trial· Frontiers in Nutrition · 2026
-
[4]
PMID 41921070 →Anti-obesity effects of probiotics beyond BMI: a critical review of human clinical trials· Letters in Applied Microbiology · 2026
-
[5]
PMID 41840664 →Efficacy of probiotic-supplemented formula in treating chronic diarrhea in children aged 6–43 months: evidence based on a randomized controlled trial· Gut Pathogens · 2026
-
[6]
PMID 41971606 →Multi‐Strain Probiotics BLa80, LRa05, and BBr60 Modulate Inflammation, Bile Acids, and Gut Microbiota in Type 2 Diabetes: A Randomized Controlled Trial· Food Science & Nutrition · 2026
-
[7]
PMID 41994268 →The enhancing therapeutic effect of neonatal jaundice by bifidobacterium through regulating inflammation and gut microbiota in combination with phototherapy—a randomized controlled trial· Frontiers in Microbiology · 2026
-
[8]
PMID 42020446 →Gut microbiome features associated with Bifidobacterium colonization predict personalized probiotic persistence patterns· Nature Communications · 2026
-
[9]
Source →Nourishing the preterm brain: Optimizing nutrition to support neurodevelopment after preterm birth· Utrecht University Repository (Utrecht University) · 2026
-
[10]
Source →Effect of probiotic supplementation on Clostridioides difficile stool concentration in hospitalized patients in coma: A preliminary study· Polish Annals of Medicine · 2026